Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 8, 2014, Pages 852-859

  Filippi, Massimo ^a   Rocca, Maria A ^a   Pagani, Elisabetta ^a   De Stefano, Nicola ^b   Jeffery, Douglas ^c   Kappos, Ludwig ^d   Montalban, Xavier ^e   Boyko, Alexei N ^f   Comi, Giancarlo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Cornerstone Health Care ^*  (United States)

^d UNIVERSITY OF BASEL   (Switzerland)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GADOLINIUM; LAQUINIMOD; N ACETYLASPARTIC ACID; PLACEBO; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN LEVEL; BRAIN SIZE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GRAY MATTER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALAMUS; TREATMENT DURATION; WHITE MATTER; ADOLESCENT; BIOASSAY; BLOOD; BRAIN; CONTROLLED CLINICAL TRIAL; DISABILITY; FEMALE; IMAGE PROCESSING; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

MRI; MULTIPLE SCLEROSIS;

ADOLESCENT; ADULT; ASPARTIC ACID; BRAIN; CREATININE; DISABILITY EVALUATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUINOLONES; THALAMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906537932     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306132     Document Type: Article

References (30)

1. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9.
2. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91. (Pubitemid 40388448)
3. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92. (Pubitemid 351842581)
4. Vollmer TL, Soelberg-Sorensen P, Arnold DL, et al. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. Mult Scler 2011;17:2.
5. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-95.
6. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-20. (Pubitemid 35285996)
7. Turner B, Lin X, Calmon G, et al. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003;9:21-7. (Pubitemid 36253691)
8. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158-70. (Pubitemid 43107851)
9. Bar-Zohar D, Agosta F, Goldstaub D, et al. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler 2008;14:719-27.
10. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11:349-60.
11. Rocca MA, Mesaros S, Pagani E, et al. Thalamic Damage and Long-term Progression of Disability in Multiple Sclerosis. Radiology 2010;257:463-9.
12. Agosta F, Rovaris M, Pagani E, et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006;129:2620-7. (Pubitemid 44522095)
13. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255-65.
14. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001;57:731-3. (Pubitemid 32783013)
15. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999;52:588-94. (Pubitemid 29075609)
16. Arnold DL. Magnetic resonance spectroscopy: imaging axonal damage in MS. J Neuroimmunol 1999;98:2-6. (Pubitemid 29295400)
17. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121(Pt 1):103-13. (Pubitemid 28045509)
18. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007;68:S72-82; discussion S91-76.
19. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6. (Pubitemid 41746873)
20. Chard DT, Jackson JS, Miller DH, et al. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010;32:223-8.
21. Filippi M, Rocca MA, Camesasca F, et al. Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76:1222-8.
22. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-4. (Pubitemid 32611437)
23. Audoin B, Ranjeva JP, Au Duong MV, et al. Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging 2004;20:765-71. (Pubitemid 39426070)
24. Audoin B, Davies GR, Finisku L, et al. Localization of grey matter atrophy in early RRMS: A longitudinal study. J Neurol 2006;253:1495-501. (Pubitemid 44950285)
25. Bruck W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 2005;252(Suppl 5):v10-15. (Pubitemid 41532350)
26. Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008;63:254-62. (Pubitemid 351355304)
27. Rovaris M, Agosta F, Sormani MP, et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003;126:2323-32. (Pubitemid 37432375)
28. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82. (Pubitemid 24205827)
29. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70. (Pubitemid 32053209)
30. Mathiesen HK, Jonsson A, Tscherning T, et al. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006;63:533-6.